Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

IMPORTANCE: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Shitara, Kohei, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles, Wyrwicz, Lucjan, Lee, Keun-Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Lee, Jeeyun, Castro, Hugo Raul, Mansoor, Wasat, Braghiroli, Maria Ignez, Karaseva, Nina, Caglevic, Christian, Villanueva, Luis, Goekkurt, Eray, Satake, Hironaga, Enzinger, Peter, Alsina, Maria, Benson, Al, Chao, Joseph, Ko, Andrew H., Wainberg, Zev A., Kher, Uma, Shah, Sukrut, Kang, S. Peter, Tabernero, Josep
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489405/
https://ncbi.nlm.nih.gov/pubmed/32880601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3370
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados